Curiosity Cube 2025: Merck’s Mobile Science Labs Tour Globally to Bring STEM Education to Students
24.4.2025 14:00:00 CEST | Business Wire | Press release
Curiosity Cube tours Europe, North America, and for the first time, Africa Mobile science lab aims to reach 60,000 students in 19 countries Interactive lessons on artificial intelligence designed to spark students’ curiosity in STEM
Merck, a leading science and technology company, today launched its global 2025 Curiosity Cube tour in Darmstadt, Germany. The solar-powered mobile science labs will bring hands-on STEM (science, technology, engineering and mathematics) experiences to students across Europe, North America, and for the first time, Africa. In 2025, the tour aims to reach 60,000 students worldwide. The initiative underscores Merck's commitment to inspiring enthusiasm for science and technology. Merck today also opened its Curiosity Labs™ STEM Center in Darmstadt with 11 interactive science lessons to complement the Curiosity Cube experience for local students year-round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424271266/en/
The mobile science labs tour Europe, North America and for the first time, Africa.
“With technological advances and scientific breakthroughs reshaping the world, it has never been more important to inspire early interest in STEM careers and prove that science can be fun,” said Tim M. Jaeger, Chief Strategy and Transformation Officer for the Life Science business sector of Merck. “With the Curiosity Cube, we are breaking down barriers to science education by bringing hands-on experiments directly to students in their local communities. This year, our new AI-focused lessons offer students a glimpse into the future of technology, while making science accessible and showing children that science is exciting.”
As artificial intelligence (AI) continues to transform daily life and work, it’s crucial that students understand how it functions – and how to use it responsibly. These early, hands-on experiences foster critical thinking and equip young people with the digital fluency they need to thrive in the future. In 2025, the Curiosity Cube introduces lessons on AI using a variety of learning tools and technologies, allowing students to explore:
- Differences between AI-generated images and real photos to better understand digital authenticity.
- How AI learns through experience and pattern recognition – just like the human brain.
- Mechanics behind AI-powered self-driving cars through hands-on activities in machine learning.
The Curiosity Cube will make its debut in Africa on June 10, 2025, with 100 events planned across Botswana, Eswatini, Lesotho, Namibia and South Africa. This expansion complements Merck’s ongoing efforts to make science education more accessible and provide students around the world with interactive STEM learning experiences.
The Curiosity Cube’s European tour will include more than 130 events, travelling to Austria, Belgium, the Czech Republic, France, Germany, Ireland, Italy, Liechtenstein, the Netherlands, Spain, Switzerland and the U.K.
The seventh North American tour with 140 scheduled events will include visits to major cities across the U.S. and Canada, including Austin, Boston, Cleveland, Houston, Kansas City, Milwaukee, Seattle, St. Louis, Toronto and more.
To learn more about the Curiosity Cube and view the 2025 tour schedule, visit TheCuriosityCube.com and follow @curiositycube_merck on Instagram.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424271266/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
Canva Announces Anthropic Collaboration to Bring AI-Powered Design to Millions17.4.2026 17:51:00 CEST | Press release
New collaboration brings Canva into Claude Design by Anthropic, turning AI-generated ideas into fully editable, on-brand designs Canva, the world’s leading all-in-one visual communication platform, today announced the next chapter in its two-year strategic collaboration with Anthropic, bringing Canva directly into the newly launched Claude Design by Anthropic Labs, one day after unveiling Canva AI 2.0 to a crowd of 6,500 people at Canva Create in Los Angeles.. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260410843169/en/ Canva and Claude Canva is also today introducing HTML importing, a new capability that makes it easy to bring interactive content generated in tools like Claude into the Canva editor for drag-and-drop collaboration, refinement, and publishing. The collaboration makes it easier for Claude Design users to turn AI-generated drafts and ideas into fully editable designs in Canva, where they become collaborative
Andersen Consulting tilføjer samarbejdsfirmaet Nuvolar17.4.2026 15:43:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform for digitale transformation gennem en samarbejdsaftale med Nuvolar, et teknologikonsulenthus med speciale i cloudbaseret softwareudvikling og avancerede Salesforce-implementeringer. Nuvolar, der blev stiftet i 2008 og har hovedsæde i Spanien, leverer end-to-end digital produktudvikling med dyb ekspertise inden for Salesforce, specialudviklede web- og mobilapplikationer, full-stack udvikling, UX/UI-design, produktledelse og langsigtede supporttjenester. Med mere end 110 fagfolk fordelt over Barcelona, Madrid, Miami og Mexico City arbejder virksomheden med kunder inden for luftfart, sundhedsvæsen, forbrugsgoder, medicinalindustrien samt hotel- og restaurationsbranchen for at designe og implementere skalerbare, forretningskritiske platforme, der optimerer driften og fremskynder den digitale transformation. "Samarbejdet med Andersen Consulting giver os mulighed for at levere vores ekspertise i en større skala," udtalte Marc Vivas, administrerende di
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom